PRQR - ProQR Therapeutics N.V. News

Sectors

PRQR

ProQR Therapeutics N.V.

2.13

1 x 2.17

2 x 2.76

bid

ask

0.16

6.99%

2 @ 07:30 PM

2.17 +0.04 (1.88%)

Ytd	5.45%
1y	-5.33%

2.12

day range

2.29

1.33

52 week range

3.10

Open	2.26	Prev Close	2.29	Low	2.12	High	2.29	Mkt Cap	300.58M
Vol	943.52K	Avg Vol	1.11M	EPS	-0.47	P/E	N/A	Forward P/E	-5.68
Beta	0.25	Short Ratio	0.31	Inst. Own	24.96%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	11-05	50-d Avg	1.88	200-d Avg	1.79	1yr Est	8.00

PRQR News

seekingalpha.com

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concep

benzinga.com

Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’

U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losse

benzinga.com

B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target o

B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) w

benzinga.com

ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analy

globenewswire.com

ProQR Announces Second Quarter 2026 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (

defenseworld.net

Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get F

defenseworld.net

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of “Moderate Buy” from Analysts

ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has received an average rating of "Moderate

seekingalpha.com

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demo

benzinga.com

Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a

benzinga.com

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche

benzinga.com

Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowe

benzinga.com

Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success

ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concur

benzinga.com

ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Tot

ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedi

globenewswire.com

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

benzinga.com

ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target

globenewswire.com

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Val

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target

benzinga.com

ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analys

globenewswire.com

ProQR Announces First Quarter 2026 Operating and Financial Results

AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected

globenewswire.com

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of it

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

zacks.com

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings

globenewswire.com

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

globenewswire.com

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (

defenseworld.net

ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter

ProQR Therapeutics (NASDAQ: PRQR) outlined multiple pipeline updates and development priorities duri

seekingalpha.com

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

globenewswire.com

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (

benzinga.com

ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Ne

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transf

globenewswire.com

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to suppor

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

globenewswire.com

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

seekingalpha.com

ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

benzinga.com

ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the ana

zacks.com

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

ProQR (PRQR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate o

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com

ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analys

benzinga.com

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and main

benzinga.com

ProQR Therapeutics Gets European Medicines Agency's Committee's Authorization For Clinical Trial App

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transf

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and main

benzinga.com

ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate, Sales $4.327M Miss $4.408M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the ana

benzinga.com

ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the ana

benzinga.com

Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target

Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Over

benzinga.com

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Marke

benzinga.com

Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9

Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperfor

benzinga.com

Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:P

benzinga.com

ProQR Therapeutics Appoints Dennis Hom As CFO

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV

benzinga.com

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and main

benzinga.com

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12

HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy

benzinga.com

This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesda

benzinga.com

Jones Trading Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $1

Jones Trading analyst Catherine Novack initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) wit